Vaxcyte (PCVX) director granted 2,194 RSUs and 11,034 options in equity award
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Vaxcyte director Olivier Brandicourt received new equity awards consisting of restricted stock units (RSUs) and stock options. He was granted 2,194 RSUs, each representing one share of Vaxcyte common stock. These RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual stockholder meeting, subject to his continuous service.
He also received stock options for 11,034 shares of common stock at an exercise price of $49.56 per share, expiring on June 15, 2036. These options vest monthly and will be fully vested on the same earlier-of-2027-or-next-meeting schedule. Following the RSU grant, he directly holds 4,699 common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
BRANDICOURT OLIVIER
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 11,034 | $0.00 | -- |
| Grant/Award | Common Stock | 2,194 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 11,034 shares (Direct, null);
Common Stock — 4,699 shares (Direct, null)
Footnotes (1)
- Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Key Figures
RSU grant: 2,194 shares
Option grant size: 11,034 shares
Option exercise price: $49.56 per share
+2 more
5 metrics
RSU grant
2,194 shares
Restricted stock units awarded to director on June 15, 2026
Option grant size
11,034 shares
Stock options granted on June 15, 2026
Option exercise price
$49.56 per share
Strike price for 11,034 stock options
Option expiration
June 15, 2036
Expiry date of granted stock options
Shares held after grant
4,699 shares
Total direct common stock holdings after RSU award
Key Terms
restricted stock units ("RSUs"), contingent right, vest, exercise price, +1 more
5 terms
restricted stock units ("RSUs") financial
"Represents the number of shares of Common Stock underlying restricted stock units ("RSUs")."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
contingent right financial
"Each RSU represents the contingent right to receive one share of the Issuer's Common Stock."
vest financial
"The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
continuous service financial
"subject to the Reporting Person's continuous service through such date."
FAQ
What insider transactions did Vaxcyte (PCVX) director Olivier Brandicourt report?
Olivier Brandicourt reported equity compensation grants from Vaxcyte, including restricted stock units and stock options. The filing shows no open-market buying or selling, only awards that increase his potential ownership if service and vesting conditions are met.
How many restricted stock units did Olivier Brandicourt receive from Vaxcyte (PCVX)?
He received 2,194 restricted stock units (RSUs), each tied to one Vaxcyte common share. These RSUs vest in full on the earlier of June 15, 2027 or the day before the next annual meeting, assuming his continuous service with the company.
What are the terms of Olivier Brandicourt’s new Vaxcyte (PCVX) stock options?
He was granted options on 11,034 shares of Vaxcyte common stock at an exercise price of $49.56 per share. The options vest monthly and fully vest by the earlier of June 15, 2027 or the day before the next annual meeting, and expire June 15, 2036.
When will Olivier Brandicourt’s Vaxcyte (PCVX) RSUs and options be fully vested?
Both the 2,194 RSUs and the 11,034 stock options are designed to fully vest by the earlier of June 15, 2027 or the day prior to Vaxcyte’s next annual stockholder meeting, provided Olivier Brandicourt maintains continuous service with the company.